These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 32468640)

  • 1. Extended endocrine therapy in premenopausal breast cancer patients: Where are we now?
    Villasco A; D'Alonzo M
    Breast J; 2020 Oct; 26(10):2018-2020. PubMed ID: 32468640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer.
    O'Regan RM; Zhang Y; Fleming GF; Francis PA; Kammler R; Viale G; Dell'Orto P; Lang I; Bellet M; Bonnefoi HR; Tondini C; Villa F; Bernardo A; Ciruelos EM; Neven P; Karlsson P; Müller B; Jochum W; Zaman K; Martino S; Geyer CE; Jerzak KJ; Davidson NE; Coleman RE; Ingle JN; van Mackelenbergh MT; Loi S; Colleoni M; Schnabel CA; Treuner K; Regan MM
    JAMA Oncol; 2024 Oct; 10(10):1379-1389. PubMed ID: 39145953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
    Mathew A; Davidson NE
    Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration.
    Francis PA
    Breast; 2019 Nov; 48 Suppl 1():S85-S88. PubMed ID: 31839169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.
    Regan MM; Pagani O; Fleming GF; Walley BA; Price KN; Rabaglio M; Maibach R; Ruepp B; Coates AS; Goldhirsch A; Colleoni M; Gelber RD; Francis PA; ;
    Breast; 2013 Dec; 22(6):1094-100. PubMed ID: 24095609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
    Colleoni M; Munzone E
    Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
    Conte B; Poggio F; Del Mastro L
    Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
    Francis PA; Pagani O; Fleming GF; Walley BA; Colleoni M; Láng I; Gómez HL; Tondini C; Ciruelos E; Burstein HJ; Bonnefoi HR; Bellet M; Martino S; Geyer CE; Goetz MP; Stearns V; Pinotti G; Puglisi F; Spazzapan S; Climent MA; Pavesi L; Ruhstaller T; Davidson NE; Coleman R; Debled M; Buchholz S; Ingle JN; Winer EP; Maibach R; Rabaglio-Poretti M; Ruepp B; Di Leo A; Coates AS; Gelber RD; Goldhirsch A; Regan MM;
    N Engl J Med; 2018 Jul; 379(2):122-137. PubMed ID: 29863451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.
    Pagani O; Francis PA; Fleming GF; Walley BA; Viale G; Colleoni M; Láng I; Gómez HL; Tondini C; Pinotti G; Di Leo A; Coates AS; Goldhirsch A; Gelber RD; Regan MM;
    J Clin Oncol; 2020 Apr; 38(12):1293-1303. PubMed ID: 31618131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: ready for prime time?
    Montagna E; Cancello G; Colleoni M
    Cancer Treat Rev; 2013 Dec; 39(8):886-90. PubMed ID: 23725877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer.
    Figg WD; Cook K; Clarke R
    Cancer Biol Ther; 2014; 15(12):1586-7. PubMed ID: 25535893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER study.
    Arecco L; Latocca MM; Blondeaux E; Riccardi F; Mocerino C; Guarneri V; Mioranza E; Bisagni G; Gasparini E; Puglisi F; Membrino A; Ferro A; Adamo V; Giovanardi F; Tamberi S; Donati S; Landucci E; Biganzoli L; Piccinini S; Pastorino S; de Azambuja E; Poggio F; Lambertini M; Del Mastro L
    Breast; 2024 Oct; 77():103769. PubMed ID: 39043079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.
    Saha P; Regan MM; Pagani O; Francis PA; Walley BA; Ribi K; Bernhard J; Luo W; Gómez HL; Burstein HJ; Parmar V; Torres R; Stewart J; Bellet M; Perelló A; Dane F; Moreira A; Vorobiof D; Nottage M; Price KN; Coates AS; Goldhirsch A; Gelber RD; Colleoni M; Fleming GF; ; ;
    J Clin Oncol; 2017 Sep; 35(27):3113-3122. PubMed ID: 28654365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
    Carlson RW; Henderson IC
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
    Jankowitz RC; McGuire KP; Davidson NE
    Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.
    Bartlett JMS; Sgroi DC; Treuner K; Zhang Y; Ahmed I; Piper T; Salunga R; Brachtel EF; Pirrie SJ; Schnabel CA; Rea DW
    Ann Oncol; 2019 Nov; 30(11):1776-1783. PubMed ID: 31504126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.
    Francis PA; Fleming GF; Láng I; Ciruelos EM; Bonnefoi HR; Bellet M; Bernardo A; Climent MA; Martino S; Bermejo B; Burstein HJ; Davidson NE; Geyer CE; Walley BA; Ingle JN; Coleman RE; Müller B; Le Du F; Loibl S; Winer EP; Ruepp B; Loi S; Colleoni M; Coates AS; Gelber RD; Goldhirsch A; Regan MM;
    J Clin Oncol; 2023 Mar; 41(7):1370-1375. PubMed ID: 36493334
    [No Abstract]   [Full Text] [Related]  

  • 19. Adjuvant endocrine therapy for premenopausal women: Type and duration.
    Francis PA
    Breast; 2017 Aug; 34 Suppl 1():S108-S111. PubMed ID: 28669713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer.
    van Hellemond IEG; Geurts SME; Tjan-Heijnen VCG
    Curr Treat Options Oncol; 2018 Apr; 19(5):26. PubMed ID: 29704066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.